Chauthaiwale V M, Therwath A, Deshpande V V
Division of Biochemical Sciences, National Chemical Laboratory, Pune, India.
Microbiol Rev. 1992 Dec;56(4):577-91. doi: 10.1128/mr.56.4.577-591.1992.
Extensive research has been directed toward the development of multipurpose lambda vectors for cloning ever since the potential of using coliphage lambda as a cloning vector was recognized in the late 1970s. An understanding of the intrinsic molecular organization and of the genetic events which determine lysis or lysogeny in lambda has allowed investigators to modify it to suit the specific requirements of gene manipulations. Unwanted restriction sites have been altered and arranged together into suitable polylinkers. The development of a highly efficient in vitro packaging system has permitted the introduction of chimeric molecules into hosts. Biological containment of recombinants has been achieved by introducing amber mutations into the lambda genome and by using specific amber suppressor hosts. Taking advantage of the limited range of genome size (78 to 105% of the wild-type size) for its efficient packaging, an array of vectors has been devised to accommodate inserts of a wide size range, the limit being 24 kbp in Charon 40. The central dispensable fragment of the lambda genome can be replaced by a fragment of heterologous DNA, leading to the construction of replacement vectors such as Charon and EMBL. Alternatively, small DNA fragments can be inserted without removing the dispensable region of the lambda genome, as in lambda gt10 and lambda gt11 vectors. In addition, the introduction of many other desirable properties, such as NotI and SfiI sites in polylinkers (e.g., lambda gt22), T7 and T3 promoters for the in vitro transcription (e.g., lambda DASH), and the mechanism for in vivo excision of the intact insert (e.g., lambda ZAP), has facilitated both cloning and subsequent analysis. In most cases, the recombinants can be differentiated from the parental phages by their altered phenotype. Libraries constructed in lambda vectors are screened easily with antibody or nucleic acid probes since several thousand clones can be plated on a single petri dish. Besides the availability of a wide range of lambda vectors, many related techniques such as rapid isolation of lambda DNA, a high efficiency of commercially available in vitro packaging extracts, and in vitro amplification of DNA via the polymerase chain reaction have collectively contributed to lambda's becoming one of the most powerful and popular tools for molecular cloning.
自20世纪70年代末人们认识到利用大肠杆菌噬菌体λ作为克隆载体的潜力以来,大量研究一直致力于开发用于克隆的多功能λ载体。对λ内在分子组织以及决定其裂解或溶原性的遗传事件的了解,使研究人员能够对其进行改造,以满足基因操作的特定要求。不需要的限制酶切位点已被改变并组合成合适的多克隆位点。高效体外包装系统的开发使得嵌合分子能够导入宿主细胞。通过在λ基因组中引入琥珀突变并使用特定的琥珀抑制宿主,实现了重组体的生物学限制。利用其高效包装所需的有限基因组大小范围(野生型大小的78%至105%),已设计出一系列载体来容纳各种大小范围的插入片段,在Charon 40中其上限为24kbp。λ基因组的中央可缺失片段可被异源DNA片段取代,从而构建出如Charon和EMBL等取代型载体。或者,小DNA片段可在不切除λ基因组可缺失区域的情况下插入,如在λgt10和λgt11载体中。此外,多克隆位点中引入许多其他理想特性,如NotI和SfiI位点(如λgt22)、用于体外转录的T7和T3启动子(如λDASH)以及完整插入片段体内切除机制(如λZAP),都促进了克隆及后续分析。在大多数情况下,重组体可通过其改变的表型与亲本噬菌体区分开来。由于数千个克隆可接种在单个培养皿上,因此用抗体或核酸探针很容易筛选在λ载体中构建的文库。除了有多种λ载体可供使用外,许多相关技术,如λDNA的快速分离、市售体外包装提取物的高效率以及通过聚合酶链反应进行DNA体外扩增,共同促成了λ成为分子克隆最强大且最受欢迎的工具之一。